Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Fosfocreatine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MVD | P53602 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fosfocreatine SCHEMBL30031412 | 1.00 | MVD (0.38) | MVD | |
| Fosfocreatine SCHEMBL31181876 | 0.98 | MVD (0.37) | MVD | |
| Fosfocreatine SCHEMBL30930087 | 0.98 | MVD (0.37) | MVD | |
| Fosfocreatine SCHEMBL29749874 | 0.86 | MVD (0.40) | MVD | |
| Fosfocreatine SCHEMBL612834 | 0.86 | — | — | |
| Fosfocreatine SCHEMBL9319928 | 0.82 | — | — | |
| Fosfocreatine SCHEMBL3026727 | 0.82 | — | — | |
| Fosfocreatine SCHEMBL24116748 | 0.81 | MVD (0.44) | MVD | |
| Fosfocreatine SCHEMBL2124030 | 0.81 | MVD (0.44) | MVD | |
| Fosfocreatine SCHEMBL65425 | 0.81 | MVD (0.44) | MVD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12280067-B2 | Formulations of creatine and cyclodextrin exhibiting improved bioavailability | PHENOLICS, LLC (US) | 2025-04-22 | — | — | US | claimed |
| US-20230055210-A1 | FORMULATIONS OF CREATINE AND CYCLODEXTRIN EXHIBITING IMPROVED BIOAVAILABILITY | PHENOLICS, LLC (US) | 2023-02-23 | — | — | US | claimed |
| US-20220211729-A1 | FORMULATIONS OF CREATINE AND CYCLODEXTRIN EXHIBITING IMPROVD BIOAVAILABILITY | PHENOLICS, LLC | 2022-07-07 | — | — | US | claimed |
| US-20210361731-A1 | Oral Formulations Containing Enriched Polyphenolic Compounds together with a Form of Creatine, a Source of Choline and Trisodium Citrate | PHENOLICS, LLC (US) | 2021-11-25 | — | — | US | claimed |
| EP-3027166-B1 | FORMULATIONS CONTAINING SPHINGANINE | EVONIK OPERATIONS GMBH (DE) | 2020-02-12 | — | — | EP | claimed |
| CN-110387405-A | A kind of (RT) RAA-CRISPR system of quick detection nucleic acid | 浙江善测禾骑士生物科技有限公司 | 2019-10-29 | — | — | CN | claimed |
| CN-109134380-A | Chloro aminooimidazole class compound and preparation method thereof, purposes and detection method | 上海慈瑞医药科技股份有限公司 | 2019-01-04 | — | — | CN | claimed |
| US-9913789-B2 | Formulations containing sphinganine | EVONIK DEGUSSA GMBH (DE) | 2018-03-13 | — | — | US | claimed |
| US-20160184204-A1 | FORMULATIONS CONTAINING SPHINGANINE | EVONIK DEGUSSA GMBH (DE) | 2016-06-30 | — | — | US | claimed |
| CN-103204875-B | Creatine phosphate sodium compound and preparation method thereof | SUN WEI | 2015-04-08 | — | — | CN | claimed |
| CN-102690285-B | Preparation method of disodium creatine phosphate | CHONGQING LUMMY PHARMACEUTICAL | 2014-12-24 | — | — | CN | claimed |
| CN-102295658-B | Refining method of disodium phosphocreatine | CHONGQING LUMMY PHARMACEUTICAL | 2014-05-07 | — | — | CN | claimed |
| CN-103204875-A | Creatine phosphate sodium compound and preparation method thereof | SUN WEI | 2013-07-17 | — | — | CN | claimed |
| CN-102690285-A | Preparation method of disodium creatine phosphate | CHONGQING LUMMY PHARMACEUTICAL | 2012-09-26 | — | — | CN | claimed |
| CN-101492470-B | Synthesis of phosphocreatine disodium salt | SHANGHAI CIRUI MEDICINE TECHNOLOGY LTD | 2012-01-11 | — | — | CN | claimed |
| CN-101492470-A | Synthesis of phosphocreatine disodium salt | SHANGHAI CIRUI MEDICINE TECHNO (CN) | 2009-07-29 | — | — | CN | claimed |
| US-4675314-A | INFUSION SOLUTION FOR ACUTE MYOCARDIAL INFACTION AND MYOCARDI UM PROTECTING AGENT DURING SURGERY | SCHIAPPARELLI FARMACEUTICI S.P.A. (IT) | 1987-06-23 | — | — | US | claimed |
| EP-0199117-A2 | New therapeutical use of phosphocreatine | SCHIAPPARELLI FARMACEUTICI S.p.A. (IT) | 1986-10-29 | — | — | EP | claimed |
| WO-2026099172-A1 | SPHINGOLIPID BASED HAIR TREATMENT | SEDERMA (FR) | 2026-05-15 | — | — | WO | disclosed |
| US-4656133-A | Method for enzymatic synthesis of isotopically labeled carbohydrates | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 1987-04-07 | — | — | US | disclosed |